Patents Examined by Eggerton Campbell
  • Patent number: 6194176
    Abstract: The present invention a provides methods for production of heterologous polypeptides using a variety recombinantly engineered secretory cell lines. The common feature of these cell lines is the absence of expression of at least one endogenous polypeptide. The host cell machinery normally used to produce the endogenous polypeptide is then usurped for the purpose of making the heterologous polypeptide. Also described are methods engineering cells for high level expression, methods of large scale protein production, and methods for treatment of disease in vivo using viral delivery systems and recombinant cell lines.
    Type: Grant
    Filed: January 17, 1997
    Date of Patent: February 27, 2001
    Assignees: Board of Regents, The University of Texas System, Betagene, Inc.
    Inventors: Christopher B. Newgard, Philippe Halban, Karl D. Normington, Samuel A. Clark, Anice E. Thigpen, Christian Quaade, Fred Kruse
  • Patent number: 6190865
    Abstract: A method of characterizing a nucleic acid molecule is disclosed. The method comprises synthesizing DNA in the presence of a reaction mixture comprising a nucleic acid template, a primer molecule, an enzyme that extends the primer so that a DNA molecule may be synthesized, four canonical deoxynucleoside triphosphates and at least one non-canonical deoxynucleoside triphosphate. The non-canonical deoxynucleoside triphosphate is incorporated into the synthesized DNA in place of a portion of only one canonical deoxynucleoside triphosphate. The synthesized DNA is treated with an N-glycosylase that excises a base portion of the non-canonical deoxynucleoside triphosphate from the synthesized DNA. The DNA is then treated in such a manner that the phosphodiester backbone of the DNA is broken at the abasic site, thus creating at least two DNA fragments. The fragments are separated according to size.
    Type: Grant
    Filed: September 27, 1995
    Date of Patent: February 20, 2001
    Assignee: Epicentre Technologies Corporation
    Inventors: Jerome J. Jendrisak, Leslie M. Hoffman, Robert E. Smith
  • Patent number: 6180339
    Abstract: Nucleic acid probes and primers are described for detecting fungi that cause disease in humans and animals, as well as spoilage of food and beverages. These probes can detect rRNA, rDNA or polymerase chain reaction products from a majority of fungi in clinical, environmental or food samples. Nucleic acid hybridization assay probes specific for Acremonium sp., Aspergillus clavatus, Aspergillus flavus, Aspergillus fumigatus, Aspergillus glaucus, Aspergillus nidulans, Aspergillus niger, Aspergillus ochraceus, Aspergillus terreus, Aspergillus unguis, Aspergillus ustus, Beauveria sp., Bipolaris sp., Blastoschizomyces sp., Blastomyces dermatitidis, Candida albicans, Candida glabrata, Candida guilliermondii, Candida kefyr, Candida krusei, Candida lusitaniae, Candida parapsilosis, Candida tropicalis, Chrysosporium sp., Cladosporium sp., Coccidioides immitis, Cryptococcus neoformans var gattii serotype B, Cryptococcus neoformans serotype A, Cryptococcus laurentii, Cryptococcus terreus, Curvularia sp., Fusarium sp.
    Type: Grant
    Filed: June 6, 1997
    Date of Patent: January 30, 2001
    Assignee: Bayer Corporation
    Inventors: Gurpreet S. Sandhu, Bruce C. Kline
  • Patent number: 6177246
    Abstract: Compositions and methods are provided for the modulation of abnormal expression of &bgr;-amyloid. oligonucleotides are provided which are specifically hybridizable with RNA or DNA encoding &bgr;-amyloid. Oligonucleotides specifically hybridizable with a translation initiation site, codon 717, codon 670 or codon 671 of RAPP are provided. Such oligonucleotides can be used for diagnostics as well as for research purposes. Methods are also disclosed for modulating &bgr;-amyloid expression in cells and tissues using the oligonucleotides provided, and for specific modulation of expression of the mutant RAPP gene. Methods for diagnosis, detection and treatment of diseases associated with abnormal &bgr;APP expression are also disclosed.
    Type: Grant
    Filed: November 16, 1998
    Date of Patent: January 23, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Susan M. Freier, David J. Ecker
  • Patent number: 6177244
    Abstract: The invention provides isolated nucleic acids molecules, designated NPG-1 nucleic acid molecules, which encode polypeptides involved in the modulation of a response in a tumor cell. The invention also provides antisense nucleic acid molecules, expression vectors containing NPG-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which an NPG-1 gene has been introduced or disrupted. The invention still further provides isolated NPG-1 polypeptides, fusion polypeptides, antigenic peptides, and anti-NPG-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: February 11, 1998
    Date of Patent: January 23, 2001
    Assignee: Beth Israel Deaconess Medical Center Inc.
    Inventors: Arthur J. Sytkowski, Meiheng Yang
  • Patent number: 6174666
    Abstract: A method of locating an inhibitory/instability sequence or sequences within the coding region of an mRNA and modifying the gene encoding that mRNA to remove these inhibitory/instability sequences by making clustered nucleotide substitutions without altering the coding capacity of the gene is disclosed. Constructs containing these mutated genes and host cells containing these constructs are also disclosed. The method and constructs are exemplified by the mutation of a Human Immunodeficiency Virus-1 Rev-dependent gag gene to a Rev-independent gag gene. Constructs useful in locating inhibitory/instability sequences within either the coding region or the 3′ untranslated region of an mRNA are also disclosed.
    Type: Grant
    Filed: March 27, 1992
    Date of Patent: January 16, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: George N. Pavlakis, Barbara K. Felber
  • Patent number: 6174668
    Abstract: An aqueous composition containing primers for opposing strands of two or more target nucleic acids can be used in polymerase chain reaction to provide simultaneously rapid and efficient amplification and detection of those nucleic acids. The primers for each target DNA differ in length by no more than 5 nucleotides and have a Tm within the range of from about 65 to about 74° C., while the Tm's are within about 5° C. of each other. Such compositions are useful in diagnostic test kits and methods for amplification and detection of multiple nucleic acids, or in “multiplexing”, using multiple capture probes. All of the capture probes have Tm's which are greater than 50° C. and are within 15° C. of each other.
    Type: Grant
    Filed: May 14, 1993
    Date of Patent: January 16, 2001
    Assignee: Johnson & Johnson Clinical Diagnostics, Inc.
    Inventors: Thomas J. Cummins, Susan Melissa Atwood, Lynn Bergmeyer, John Bruce Findlay, John W. H. Sutherland, JoAnne H. Kerschner
  • Patent number: 6159713
    Abstract: Methodology is provided for developing probes for identifying sequence differences between two related DNA populations, sets of DNA fragments or collections of restriction-endonuclease-cleaved DNA or cDNA. The method employs an initial stage to obtain a representation of both DNA populations, namely using the PCR to produce relatively short fragments, referred to as amplicons. Tester amplicons containing target DNA, sequences of interest, are ligated to adaptors and mixed with excess driver amplicons under melting and annealing conditions, followed by PCR amplification. The process may be repeated so as to greatly enrich the target DNA. Optionally, the target DNA may then be cloned and the DNA used as probes.
    Type: Grant
    Filed: July 14, 1998
    Date of Patent: December 12, 2000
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Michael Wigler, Nikolai Lisitsyn
  • Patent number: 6156515
    Abstract: Disclosed are nucleic acid and amino acid sequences encoded by a novel, prostate specific gene (UC41) and diagnostic techniques for the detection of human prostate cancer utilizing such nucleic acid and amino acid sequences. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. Methods of treatment for prostate cancer utilizing antisense constructs or antibodies specific for UC41 gene products are also described.
    Type: Grant
    Filed: February 9, 1999
    Date of Patent: December 5, 2000
    Assignee: Urocor, Inc.
    Inventors: Gang An, Robert Veltri
  • Patent number: 6150106
    Abstract: The present invention relates to a procedure for the qualitative and/or quantitative analysis of biological substances, which are preferably biological substances, that are present in a conductive liquid medium, with the aid of at least one affinity sensor that includes at least one structure that includes at least one semiconductor material, which is coated on one of its surface with at least one layer of an isolating material, which in turn is affixed adhesively to at least one sensitive membrane, which is in contact with the conductive medium and which includes ligands that are complementary to the biological substances in question and which are capable of, and suitable for, forming pairs specifically with the latter biological substances, with the said procedure being characterized by the fact that it consists essentially of applying a voltage between the semiconductor and the conductive medium; of gathering the variations in the electrical signals induced by a charge- effect phenomenon directly and essen
    Type: Grant
    Filed: August 21, 1998
    Date of Patent: November 21, 2000
    Inventors: Jean-Rene Martin, Eliane Souteyrand, Marcus Francois Lawrence, Susan Rosalie Mikkelsen
  • Patent number: 6143498
    Abstract: The present invention relates to a novel human antimicrobial peptide which is a member of the defensin superfamily. In particular, isolated nucleic acid molecules are provided encoding the human antimicrobial peptide. Antimicrobial peptide are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for detecting disorders related to the immune system and therapeutic methods for such disorders.
    Type: Grant
    Filed: May 14, 1998
    Date of Patent: November 7, 2000
    Assignee: Human Genome Sciences, Inc.
    Inventors: Henrik S. Olsen, Steven M. Ruben
  • Patent number: 6143494
    Abstract: The ability to rapidly detect wild polioviruses in clinical specimens is a major concern for the world-wide eradication of polioviruses. Provided is a method of detecting polioviruses of all three serotypes from viral isolates of clinical specimens using a pair of degenerate PCR primers. This primer set, which uses deoxyinosine residues to compensate for third position mismatches at specific positions, recognizes nucleotide sequences near the receptor binding site of polioviruses. These sequences are unique to polioviruses and are absolutely conserved at the amino acid level. As a result, these PCR primers do not recognize nonpoliovirus enteroviruses. All poliovirus serotypes (40 poliovaccine related genotypes and 120 wild poliovirus genotypes from around the world) tested positive. All 14 prototype strains of nonpoliovirus enteroviruses tested negative.
    Type: Grant
    Filed: September 25, 1997
    Date of Patent: November 7, 2000
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventor: David R. Kilpatrick
  • Patent number: 6127129
    Abstract: Disclosed is a process to construct multi-component biomolecule or cellular arrays suitable for use in SPR imaging studies of large molecule, cellular/molecular, and cell/cell interactions. The success of the procedure hinges on the use of a reversible protecting group to modify reversibly .omega.-functionalized alkanethiols self-assembled on metal substrates.
    Type: Grant
    Filed: August 5, 1999
    Date of Patent: October 3, 2000
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Robert M. Corn, Anthony G. Frutos, Jennifer M. Brockman
  • Patent number: 6120988
    Abstract: Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent (HEV) are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in individuals infected with the viral hepatitis agent. This protein is useful in a diagnostic method for detecting infection by the enterically transmitted agent. Specific epitopes have been identified that are reactive with sera of individual infected with different strains of HEV. Also disclosed are DNA probes derived from a cloned sequence of the viral agent. These probes are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, by using probe-specific amplification of virus-derived DNA fragments.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 19, 2000
    Assignees: Genelabs Technologies, Inc., The United States of America
    Inventors: Gregory R. Reyes, Patrice O. Yarbough, Daniel W. Bradley, Krzysztof Z. Krawczynski, Albert Tam, Kirk E. Fry
  • Patent number: 6117632
    Abstract: A method of identifying a peptide which permits or facilitates the transport of an active agent through a human or animal tissue. A predetermined amount of phage from a random phage library or preselected phage library is plated unto or brought into contact with a first side, preferably the apical side, of a tissue sample or polarized tissue cell culture. At a predetermined time, the phage which is transported to a second side of the tissue opposite the first side, preferably the basolateral side, is harvested to select transported phage. This modified phage is amplified in a host. This cycle of events is repeated (using the transported phage produced in the most recent cycle) a predetermined number of times to obtain a selected phage library containing phage which can be transported from the first side to the second side.
    Type: Grant
    Filed: November 8, 1996
    Date of Patent: September 12, 2000
    Assignee: Elan Corporation, plc
    Inventor: Daniel Joseph O'Mahony
  • Patent number: 6117634
    Abstract: An improvement over the standard Sanger Method for nucleic acid sequencing is described. The novel method does not require denaturation of double-stranded template; rather, sequencing can be carried out directly on the double-stranded template. Embodiments are described with and without oligonucleotide primers.
    Type: Grant
    Filed: March 6, 1997
    Date of Patent: September 12, 2000
    Assignee: The Reagents of the University of Michigan
    Inventors: John P. Langmore, Vladimir L. Markarov
  • Patent number: 6114118
    Abstract: The present invention relates to materials and methods for identifying animals that are resistant or susceptible to diseases associated with intracellular parasites such as brucellosis, tuberculosis, paratuberculosis and salmonellosis. More particularly, the present invention relates to the identification of a gene, called NRAMP1, which is associated with the susceptibility or resistance of an animal, such as an artiodactyla to diseases such as brucellosis, tuberculosis, paratuberculosis and salmonellosis. Still more particularly, the present invention relates to the identification of specific sequences of bovine NRAMP1 which associate with resistance or susceptibility to ruminant brucellosis, tuberculosis, paratuberculosis and salmonellosis, and to the method of identifying said sequences to identify animals who are susceptible or resistant to disease.
    Type: Grant
    Filed: July 30, 1997
    Date of Patent: September 5, 2000
    Assignees: Texas A&M University System, McGill University
    Inventors: Joe W. Templeton, Jianwei Feng, L. Garry Adams, Erwin Schurr, Philippe Gros, Donald S. Davis, Roger Smith, III
  • Patent number: 6114116
    Abstract: The invention provides oligonucleotides and their complements that can be used as allele-specific probes or primers for sequencing, oligonucleotide probe hybridization, and allele-specific amplification. Such oligonucleotides can be used, for example, to facilitate genetic distinction between individual plants in plant populations.
    Type: Grant
    Filed: March 7, 1997
    Date of Patent: September 5, 2000
    Inventors: Bertrand Lemieux, Benoit S. Landry, Ronald J. Sapolsky
  • Patent number: 6110707
    Abstract: The present invention a provides methods for production of heterologous polypeptides, for example amylin, using recombinantly engineered cell lines. Also described are methods engineering cells for high level expression, methods of large scale heterologous protein production, methods for treatment of disease in vivo using viral delivery systems and recombinant cell lines, and methods for isolating novel amylin receptors.
    Type: Grant
    Filed: January 17, 1997
    Date of Patent: August 29, 2000
    Assignees: Board of Regents, The University of Texas System, Betagene, Inc.
    Inventors: Christopher B. Newgard, Philippe Halban, Karl D. Normington, Samuel A. Clark, Anice E. Thigpen, Christian Quaade, Fred Kruse, Dennis McGarry
  • Patent number: 6110710
    Abstract: The present invention is directed to methods for resisting or promoting template independent nucleotide addition to the 3' terminus of a DNA duplex. The process comprises amplifying a target nucleic acid using primers which comprise a 5' terminal sequence which resists or promotes non-templated nucleotide addition to the 3' terminus of the complementary nucleic acid strand. The invention is also directed to a kit for cloning 3' nucleotidylated duplex DNA.
    Type: Grant
    Filed: April 14, 1998
    Date of Patent: August 29, 2000
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Jeffrey R. Smith, John D. Carpten, Michael J. Brownstein